GLP-1 (Glucagon-like Peptide-1) drugs such as bliraglutide, semaglutide, and dulaglutide/b are originated for type 2 diabetic treatments and they

Glucagon-like peptide-1 receptor agonists lower the risk of heart attack and stroke in type 2 diabetes.

Glucagon-like peptide-1 receptor agonists lower the risk of heart attack and stroke in type 2 diabetes.

Highlights: Glucagon-like peptide-1 receptor agonists reduce major cardiovascular events in type 2 diabetes R

Public interest in GLP‑1 receptor agonists has exploded in recent years. These medicines, known as GLP‑1 RAs, include drugs like semaglutide,...

TUESDAY, Nov. 25, 2025 -- Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use with subsequent prepregnancy or early pregnancy discontinuation is...

New research is shedding light on how weight-loss and diabetes medications like Ozempic, Wegovy, and Mounjaro affect not only appetite but also the...

New research is shedding light on how weight-loss and diabetes medications like Ozempic, Wegovy, and Mounjaro affect not only appetite but also the...

A new study from the University of California San Diego has found that popular diabetes and weight-loss medications might also help people with colon...

Two major new studies have revealed that a widely used class of diabetes medications—known as SGLT2 inhibitors—can strongly protect the kidneys,...